genetic mutation Obesity
Conditions
Interventions
-patient questionnaires
-blood sampling for PK purpose
Sub-studies (if consented by patient):
24-hour pharmacokinetic study
Ambulatory blood pressure monitoring
Energy expenditure assessment
Quantitat
LEPR deficiency
obesity
setmelanotide
Sponsors
RHYTHM pharmaceuticals
Eligibility
Age
2 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Bi-allelic, homozygous or compound heterozygous (a;different gene mutation on each allele) genetic status for either the LEPR genes, with the ;loss-of-function (LOF) variant for each allele conferring a severe obesity phenotype.;2. Age 12 years and above.;3. If adult age *18 years, obesity with body mass index (BMI);* 30 kg/m2; if child or adolescent, obesity with weight > 97th percentile for age on growth chart assessment.;4. Study participant and/or parent or guardian can communicate well with the investigator, to understand and comply with the requirements of the study, and can understand and sign the written ;informed consent/assent, after being informed about the study.;5. Female participants of child-bearing potential must agree to use contraception as outlined in the protocol. Female participants of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post- menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal lab range), ;or failure to have progressed to Tanner Stage V and/or failure to have achieved menarche, do not require contraception during the study.;6. Male participants with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study. Male patients must not donate sperm during and for 90 days following their participation in the study.
Exclusion criteria
Exclusion criteria: 1. Recent intensive (within 2 months) diet and/or exercise;regimen with or without the use of weight loss agents including herbal medications, that has resulted in weight loss or weight stabilization. Patients may be reconsidered approximately 1 month ;after cessation of such intensive regimens.;2. Prior gastric bypass surgery resulting in >10% weight loss durably maintained from the baseline pre-operative weight with no evidence of weight regain. Specifically, patients may be considered if surgery was not successful, or resulted in <10% weight loss compared to pre-operative baseline weight or clear evidence of weight regain after an initial response to bariatric surgery. All patients with a history of bariatric surgery must be discussed with, and receive approval from ;Rhythm prior to enrollment.;3. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other Diagnostic and Statistical Manual of Mental Disorders (DSM-III) disorders that the investigator believes will interfere significantly with study compliance.;4. A Patient Health Questionnaire-9 (PHQ-9) score of * 15.;5. Any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS). Any lifetime history of a suicide attempt, or any suicidal behavior in the last month.;6. Current, severe stable restrictive or obstructive lung disease due to extreme obesity, evidence of significant heart failure (NYHA Class 3 or greater), or oncologic disease, if these were severe enough to interfere with the study and/or would confound the results. Any such patients should be discussed with the sponsor prior to inclusion.;7. History of significant liver disease or liver injury, or current liver assessment for a cause of abnormal liver tests [as indicated by abnormal liver function tests, alanine transaminase (ALT), ;aspartate transaminase (AST), alkaline phosphatase, or serum bilirubin (> 2.0 x upper limit of normal (ULN) for any of these tests)] for an etiology other than non-alcoholic fatty liver disease ;(NAFLD). Thus, any underlying etiology besides NAFLD, including diagnosed non-alcoholic steatohepatitis (NASH), other causes of hepatitis, or history of hepatic cirrhosis will be exclusionary, but the presence of NAFLD would not be exclusionary.;8. History or presence of impaired renal function as indicated by clinically significant abnormal creatinine, blood urea nitrogen (BUN), or urinary constituents (e.g., albuminuria) or moderate to severe renal dysfunction as defined by the Cockcroft Gault equation < 30 mL/min.;9. History or close family history (parents or siblings) of skin cancer or melanoma, or patient history of ocular-cutaneous albinism.;10. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions, determined as part of a screening comprehensive skin evaluation performed by a qualified dermatologist. Any concerning lesions identified during the screening period will be biopsied and results known to be benign prior to enrollment. If the pre- treatment biopsy results are of concern, the patient may need to be excluded from the study.;11. Volunteer is, in the opinion of the Study Investigator, not suitable to participate in the study.;12. Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing.;13. Significant hypersensitivity to study drug.;14. Inability to comply with QD injection regimen.;15. Patients who have been placed in an instituti
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in patients with LEPR deficiency obesity due to rare bi-allelic or loss-of function mutations at the end of 1 year of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary To assess the effect of setmelanotide, over one year, on: * Safety and tolerability of setmelanotide (including blood pressure [BP] and heart rate [HR]). * Hunger. * Percent change in body fat mass. * Glucose parameters: fasting glucose, glycated hemoglobin (HbA1c), oral glucose tolerate test (OGTT) with focus on parameters of insulin sensitivity. * Waist circumference. * During withdrawal from drug: reversal of weight and hunger reduction during the double-blind placebo controlled withdrawal period. Tertiary To assess the effect of setmelanotide, over one year, on: * Percent change in total body mass, non-bone lean mass, and bone density. * Fasting lipid (cholesterol and triglyceride) panel. * Pharmacokinetics of setmelanotide. * C-reactive protein. Dose response of setmelanotide through titration procedures. * Changes in quality of life and health status. Exploratory To assess the effect of setmelanotide, over one year, on: * Change in pubertal development for participants who have yet to reach Tanner Stage V. * ABPM, skin pigmentation measured by spectrophotometer, energy expenditure, and 24-hour pharmacokinetic profile, only for patients participating in these sub-studies. * Hormonal, neuroendocrine, metabolic and inflammatory analytes and biomarker assays. * If identified, a pharmacokinetic/pharmacodynamics (PK/PD) response employing a suitable endocrine biomarker predictive of setmelanotide target engagement, agonism and efficacy through activation of the MC4R. * If feasible, correlations of bi-allelic or loss-of-function LEPR genetic mutations and LEPR deficiency due to diverse allelic variants with the magnitude of setmelanotide efficacy endpoints. | — |
Countries
France, Germany, Netherlands, United Kingdom
Outcome results
None listed